Philadelphia University + Thomas Jefferson University

Schneider, Jay S.

< Back

Profile

jss101

Jay S. Schneider, PhD

Contact Dr. Schneider

1020 Locust Street
Jefferson Alumni Hall, Suite 521
Philadelphia, PA 19107

(215) 503-0370

Medical School

PhD, SUNY at Stony Brook - 1981

University Appointment

Professor, Department of Pathology, Anatomy & Cell Biology

Research and Clinical Interests

Basic, clinical and translational research on cognitive and motor aspects of Parkinson's disease with focuses on both symptomatic and neuroprotective treatment strategies; basic and clinical research on developmental neurotoxicology with an emphasis on lead-induced damage to the brain.

Publications

Most Recent Peer-Reviewed Publications

  1. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores
  2. Developmental lead and/or prenatal stress exposures followed by different types of behavioral experience result in the divergence of brain epigenetic profiles in a sex, brain region, and time-dependent manner: Implications for neurotoxicology
  3. Strain specific effects of low level lead exposure on associative learning and memory in rats
  4. Sex- and brain region- specific effects of prenatal stress and lead exposure on permissive and repressive post-translational histone modifications from embryonic development through adulthood
  5. Caffeine, creatine, GRIN2A and Parkinson's disease progression
  6. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1
  7. Sex-dependent effects of lead and prenatal stress on post-translational histone modifications in frontal cortex and hippocampus in the early postnatal brain
  8. Effects of low level lead exposure on associative learning and memory in the rat: Influences of sex and developmental timing of exposure
  9. Epigenetic mechanisms of adverse neurodevelopment in response to lead exposure and prenatal stress and the combination: The road ahead
  10. Intraventricular sialidase administration enhances GM1 ganglioside expression and is partially neuroprotective in a mouse model of Parkinson's disease
  11. Predictors of functional decline in early Parkinson's Disease: NET-PD LS1 Cohort
  12. Caffeine and progression of Parkinson disease: A deleterious interaction with creatine
  13. Pioglitazone in early Parkinson's disease: A phase 2, multicentre, double-blind, randomised trial
  14. Effects of chronic manganese exposure on attention and working memory in non-human primates
  15. Relationship between motor symptoms, cognition, and demographic characteristics in treated mild/moderate Parkinson's disease
  16. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding
  17. Effect of creatine monohydrate on clinical progression in patients with parkinson disease: A randomized clinical trial
  18. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - Baseline findings of a multicenter trial
  19. The neurobiological basis of cognitive impairment in Parkinson's disease
  20. Genetic diversity influences the response of the brain to developmental lead exposure